^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
NHS Scotland Grants Trastuzmab Deruxtecan Approval for Use in Pretreated HER2+ Metastatic Breast Cancer
Excerpt:
The Scottish Medicines Consortium (SMC) has accepted fam-trastuzumab deruxtecan-nxki (Enhertu) as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy....The advice is based on findings from the pivotal phase 3 DESTINY-Breast03 trial (NCT03529110), in which trastuzumab deruxtecan led to a 12-month progression-free survival (PFS) rate of 75.8%...
Source:
Title:
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
Published date:
05/25/2023
Excerpt:
cORR was 37.8% (95% CI, 27.3-49.2%) in the 5.4 mg/kg arm and 27.5% (95% CI, 14.6-43.9%) in the 6.4 mg/kg arm (all partial responses in both arms)….T-DXd showed promising antitumor activity in pts with HER2+ mCRC at both 5.4 and 6.4 mg/kg doses.
DOI:
10.1200/JCO.2023.41.16_suppl.3501
Trial ID:
Source:
Title:
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Published date:
05/04/2021
Excerpt:
For the 53 (68%) patients with HER2-positive tumours (cohort A), a confirmed objective response was reported in 24 (45·3%, 95% CI 31·6–59·6) patients after a median follow-up of 27·1 weeks (IQR 19·3–40·1)....Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer...
DOI:
https://doi.org/10.1016/S1470-2045(21)00086-3
Trial ID:
Source:
Title:
Trastuzumab Deruxtecan DESTINY for Some Cancers
Published date:
06/02/2020
Excerpt:
It also elicited high response rates in phase II trials of HER2-mutant non-small cell lung cancer and HER2-positive colorectal cancer.
DOI:
10.1158/2159-8290.CD-ND2020-011
Source:
Title:
Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial
Published date:
05/29/2020
Excerpt:
The primary endpoint of confirmed objective response rate (ORR), assessed by independent central review, showed 45.3% of patients with HER2-positive (defined as IHC3+ or IHC2+/ISH+) advanced colorectal cancer treated with Enhertu monotherapy (6.4mg/kg) achieved a tumour response.
